China Resources Double-Crane Pharmaceutical Co Ltd

600062 • SHG

¥16.24+¥0.32 (2.01%)

Estimate

P/E

10.4

EPS

1.56

Beta

-0.076

Growth

Revenue, YoY

5.48%

Net income, YoY

-1.58%

FCF, YoY

35.24%

Forecast

P/E (FWD)

8.9

EPS (FWD)

1.83

About the company

Ticker

600062

ISIN

CNE000000Q94

Country

China

Sector (GICS)

Healthcare

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People's Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiary of Beijing Pharmaceutical Group Co., Ltd.

Frequently asked questions

What sector does China Resources Double-Crane Pharmaceutical Co Ltd (600062) operate in?

China Resources Double-Crane Pharmaceutical Co Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is China Resources Double-Crane Pharmaceutical Co Ltd (600062) current stock price?

As of the latest data, China Resources Double-Crane Pharmaceutical Co Ltd stock price is CN¥16.24, with a previous close of CN¥15.92. China Resources Double-Crane Pharmaceutical Co Ltd gained CN¥0.32 in the last trading session, representing a 2.01% increase.

What is China Resources Double-Crane Pharmaceutical Co Ltd (600062) current market capitalization?

China Resources Double-Crane Pharmaceutical Co Ltd market cap is approximately 16.87 billion.

What is China Resources Double-Crane Pharmaceutical Co Ltd (600062) Earnings Per Share (EPS)?

The trailing EPS is CN¥1.56, and the forward EPS is CN¥1.83.

What is China Resources Double-Crane Pharmaceutical Co Ltd (600062) Price-to-Earnings (P/E) ratio?

China Resources Double-Crane Pharmaceutical Co Ltd current P/E ratio is 10.41, with a forward P/E of 8.87.

What is China Resources Double-Crane Pharmaceutical Co Ltd (600062) EBITDA?

China Resources Double-Crane Pharmaceutical Co Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 528.60 million.

Does China Resources Double-Crane Pharmaceutical Co Ltd (600062) pay dividends?

No. China Resources Double-Crane Pharmaceutical Co Ltd does not pay a dividend.

What is China Resources Double-Crane Pharmaceutical Co Ltd (600062) beta (volatility) score?

China Resources Double-Crane Pharmaceutical Co Ltd has a beta of -0.076, indicating lower volatility than the overall market.